Roche says drug slows spread of lymphatic cancer

12/8/2003 | Reuters

Roche Holding AG said its MabThera drug, when used with standard chemotherapy, almost doubles the time for the slow form of non-Hodgkin's lymphoma to worsen compared with chemotherapy alone. Roche said the drug may provide hope for a "durable remission" for some patients, and the firm plans to seek regulatory approval for the new use in early 2004.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX